Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U-DANCE-anti-AML WT1-loaded cord blood-derived dendritic cell vaccination trial after cord blood transplantation
NL-OMON44046Phase 2Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2016
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of WT1 CBDC vaccine in acute myeloid leukemia (AML) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Dose-limiting toxicity and acute graft-versus-host disease and One-year WT1-positive AML relapse-free survival. Planned start Sep 2016; status: withdrawn.
02
Drugs
WT1 CBDC vaccine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON44046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44046.